PTC Therapeutics traded at $41.85 this Friday July 1st, increasing $1.79 or 4.47 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics gained 54.03 percent. Over the last 12 months, its price fell by 2.88 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 40.72 by the end of this quarter and at 37.49 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,459.00 48.00 1.41% 48.87%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Cytokinetics 41.00 1.71 4.35% 98.93%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Ironwood Pharmaceuticals 11.53 0 0% -8.35%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Novartis 80.69 -0.96 -1.18% -4.57%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Roche Holding 319.35 -3.25 -1.01% -9.66%
Sangamo BioSciences 4.28 0.14 3.38% -63.45%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
TG Therapeutics 4.57 0.32 7.53% -88.61%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%
Xencor 28.86 1.49 5.44% -18.43%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

PTC Therapeutics
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).